WO2002085905A1 - Nouveaux derives d'adenine - Google Patents
Nouveaux derives d'adenine Download PDFInfo
- Publication number
- WO2002085905A1 WO2002085905A1 PCT/JP2002/003727 JP0203727W WO02085905A1 WO 2002085905 A1 WO2002085905 A1 WO 2002085905A1 JP 0203727 W JP0203727 W JP 0203727W WO 02085905 A1 WO02085905 A1 WO 02085905A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- pyridyl
- ocoome
- propyl
- butyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Definitions
- the present invention relates to an adenine derivative useful for prevention or treatment of viral diseases such as hepatitis B and C and AIDS, cancer disease and the like, and an interferon-inducing agent, an antiviral agent comprising the same as an active ingredient,
- the present invention relates to drugs such as an anticancer drug, a type 2 helper T cell selective immune response inhibitor, an antiallergic agent and an immune response regulator.
- Interferon is one of the most important factors involved in protection against infection and immune regulation, and has already been put into practical use as a therapeutic agent for hepatitis B and C or an immunotherapeutic agent for cancer.
- hepatitis C is virtually the only treatment.
- Interferon is a polypeptide with a molecular weight of about 20,000, manufactured by genetic recombination or cell culture, and can be administered only by injection. Therefore, there is a demand for an orally administrable inducer.
- double-stranded nucleic acids derived from viruses and other organisms, and high molecular polymers such as poly (I): poly (C) and polycarboxylate are known as substances having an interferon-inducing effect.
- double-stranded nucleic acids and high molecular weight polymers have problems in terms of antigenicity, danger of contamination by pathogenic microorganisms, biological stability, etc., and because of their high molecular weight, development as oral agents is difficult. is there.
- R-837 imidazoquinoline derivative
- imiquimod Another imidazoquinoline derivative, R-837 (imiquimod)
- R-837 is also known as another small molecule interferon inducer.
- the interferon-inducing activity of R-837 is low and its development in the oral drug field has been discontinued due to side effects.
- purine derivatives have an interferon-inducing effect (W099-28321).
- these compounds were not always sufficient in terms of gastrointestinal absorption due to their low water solubility.
- helper T cells play a central role in the immune response.
- TM cells and Th2 cells
- cytokines produced by the activation of Thl cells include interleukin-2 (IL-2) and interferon- ⁇ (IFN-r)
- the products produced from TM cells include interleukin-4 (IL-4) and interleukin-5 (IL-5).
- IL-4 interleukin-4
- IL-5 interleukin-5
- Thl side site activation activates macrophages and natural killer cells, and is mainly involved in cell-mediated immunity such as protection against infection with viruses and bacteria.
- Th2-side cytokines are involved in humoral immunity such as antibody production from B cells.
- IL-4 induces B cells to produce IgE antibodies and has a cell differentiation / proliferation effect.
- IL-5 has activities such as activation of eosinophils, promotion of differentiation and proliferation, and longevity, and often plays an important role in allergic inflammation.
- an increase in these Th2-side cytokines has been observed in affected areas of patients with allergic unilateral inflammation mainly composed of Th2 cells such as asthma and atopic dermatitis.
- Steroids are often used to treat these disorders, but the problem is that long-term administration of steroids can cause a wide range of side effects (diabetes, osteoporosis, adrenal insufficiency, moon face, etc.) .
- steroids act suppressively on both Thl and Th2 T cells, suppression of Thl cells may cause infection. Based on the above, it is expected that a drug that selectively suppresses the immune response on the ⁇ 2 side will be a safe therapeutic drug for allergic diseases without causing infectious diseases. Disclosure of the invention
- an object of the present invention is effective for the prevention or treatment of viral diseases such as hepatitis B and C, AIDS, cancer diseases and diseases caused by type 2_ helper T cells, It is an object of the present invention to provide a compound which is a small molecule which can be administered orally and which has further improved physical properties (eg, solubility, pharmacokinetics, etc.).
- the present inventors have conducted intensive studies. As a result, the adenine derivative having a specific structure has remarkable interferon-inducing activity and type 2 -helper T cell-selective immune response inhibitory activity, It was found that the present invention was excellent, and completed the present invention.
- the present invention includes the following inventions.
- X represents NR 3 (R 3 is a hydrogen atom or an alkyl group having 1 to 3 carbon atoms), an oxygen atom, or a sulfur atom;
- R 1 is a substituted or unsubstituted alkyl group, Or an unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group;
- R 2 represents a hydroxyl group, a mercapto group, and having 1 to 8 carbon atoms.
- Y represents an substituted or unsubstituted naphthalene ring or a substituted or unsubstituted nitrogen atom, an oxygen atom, and a sulfur atom;
- One is selected or two of the the fused 2-ring aromatic containing hetero atoms represent a heterocyclic ring.
- R 1 is an alkyl group having 1 to 8 carbon atoms, an alkenyl group having 2 to 8 carbon atoms, an alkynyl group having 2 to 8 carbon atoms, and an alkoxyalkyl group having 2 to 8 carbon atoms.
- the compound according to the above (1) which is a hydroxyalkyl group having 1 to 8 carbon atoms, an aryl group, a heteroaryl group, an aralkyl group, or a heteroalkyl group.
- R 1 is an alkyl group having 1 to 6 carbon atoms. Or the compound of (2).
- Y is an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, a hydroxyl group, a mercapto group, an alkylthio group having 1 to 4 carbon atoms, a halogen atom
- Y is a pyridine ring
- Y is an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, a hydroxyl group, a mercapto group, an alkylthio group having 1 to 4 carbon atoms, a halogen atom,
- a pyridine ring optionally having a substituent selected from the group consisting of an amino group, a dialkylamino group having 2 to 8 carbon atoms, a monoalkylamino group having 1 to 4 carbon atoms, a pyrrolidinyl group, a piperidino group and a morpholino group;
- R 1 is an alkyl group having 1 to 6 carbon atoms
- R 2 is a hydroxyl group.
- a medicine comprising the compound according to any one of the above (1) to (10) as an active ingredient
- An interferon inducer comprising, as an active ingredient, the compound according to any of (1) to (10).
- An antiviral agent comprising the compound according to any one of the above (1) and (10) as an active ingredient.
- An anticancer agent comprising the compound according to any one of (1) and (10) as an active ingredient.
- a type 2 helper T cell selective immune response inhibitor comprising the compound according to any one of (1) and (10) as an active ingredient.
- An anti-allergic agent comprising as an active ingredient the compound according to any one of (1) to (10).
- An immune response modulator comprising the compound according to any one of (1) to (10) as an active ingredient.
- the alkyl group, alkenyl group or alkynyl group for R 1 is preferably an alkyl group having 1 to 8 carbon atoms, an alkenyl group having 2 to 8 carbon atoms, or an alkynyl group having 2 to 8 carbon atoms.
- substituent of the alkyl group, alkenyl group or alkynyl group in R 1 include a hydroxyl group, an alkoxy group having 1 to 8 carbon atoms, an aryl group, a heteroaryl group, and a halogen atom (such as chlorine, fluorine, bromine, and iodine).
- alkenyl group or alkynyl group for R 1 an alkoxyalkyl group having 2 to 8 carbon atoms, a hydroxyalkyl group having 1 to 8 carbon atoms, an aralkyl group, and Heteroarylalkyl groups and the like are preferred.
- alkyl group having 1 to 8 carbon atoms examples include a methyl group, an ethyl group, a 1-propyl group, a 2-propyl group, a tributyl group, a 2-butyl group, a 1-pentyl group, a 2-pentyl group, -Hexyl, 2-hexyl, 1-heptyl, 2-heptyl, 3_heptyl, octyl, 2-methylpropyl, 2-methylbutyl, 3-methylbutyl, 2-methylpentyl Group, 3-methylpentyl, 4-methylpentyl, methylhexyl, methylheptyl, 1,1-dimethylethyl, 1,1-dimethylpropyl, 2-ethylhexyl, cyclopentylmethyl, cyclo Hexylmethyl, cyclopropyl, cyclobutyl, cyclopentyl, methylcyclopentyl, cyclohex
- alkenyl group having 2 to 8 carbon atoms examples include a bier group, an aryl group, a chloro group, a toppropenyl group, a cyclopentenyl group, a cyclopentenyl group, and a cyclohexenyl group.
- alkynyl group having 2 to 8 carbon atoms examples include an ethenyl group, a propynyl group and a butynyl group.
- hydroxyalkyl group having 1 to 8 carbon atoms examples include 1-hydroxyethyl group, 2-hydroxyethyl group, 1-hydroxypropyl group, 2-hydroxypropyl group, 3-hydroxypropyl group, and 1-hydroxybutyl Group, 2-hydroxybutyl group, 3-hydroxybutyl group, 4-hydroxybutyl group and the like.
- aralkyl group examples include a benzyl group, a triphenyl group, a 2-phenyl group, a phenylpropyl group and a phenylbutyl group.
- heteroarylalkyl group examples include a 4-pyridylmethyl group and a 3_pyridylmethyl group.
- alkoxyalkyl group having 2 to 8 carbon atoms examples include a methoxymethyl group, a 2-methoxyethyl group, a 3-methoxypropyl group, a 4-methoxybutyl group, an ethoxymethyl group, a 2-ethoxyhexyl group, and a 3-ethoxypropyl group.
- each substituent represented by R 1 above may have a substituent such as an alkyl group, a hydroxyl group, a mercapto group, a halogen atom, an amino group, an alkoxy group, and the like.
- the aryl or heteroaryl group for R 1 includes phenyl, 1-naphthyl, 2-naphthyl, 2-pyridyl, 3-pyridyl, 4_pyridyl, Examples thereof include a 2-pyrazinyl group, a 3-pyrazinyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group, a 5-pyrimidinyl group, a 2-furyl group, a 3-furyl group, a 2-phenyl group, and a 3-phenyl group.
- the above aryl group or heteroaryl group may be unsubstituted or may have a substituent.
- Examples of the substituent include an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, a hydroxyl group, a mercapto group, and a carbon number.
- Examples thereof include an alkylthio group having 1 to 4 atoms, a halogen atom, an amino group, a dialkylamino group having 2 to 8 carbon atoms, a monoalkylamino group having 1 to 4 carbon atoms, and a methylenedioxy group.
- Examples of the alkyl group having 1 to 4 carbon atoms include a methyl group, an ethyl group, a 1-propyl group, a 2-propyl group, and a 1-butyl group.
- Examples thereof include a butyl group and a 2-butyl group.
- Examples of the alkoxy group having 1 to 4 carbon atoms include a methoxy group, an ethoxy group, a 1-propoxy group, a 2-propoxy group, a 1-butoxy group and a 2-butoxy group.
- Examples of the dialkylamino group having 2 to 8 carbon atoms include a dimethylamino group, a dimethylamino group, a dipropylamino group, a dibutylamino group, an ethylmethylamino group, and a methylpropylamino group.
- Examples of the monoalkylamino group having 1 to 4 carbon atoms include a methylamino group, an ethylamino group, a propylamino group, and a butylamino group.
- Examples of the alkylthio group having 1 to 4 carbon atoms include a methylthio group, an ethylthio group, a 1-propylthio group, a 2-propylthio group, a 1-butylthio group, a 2-butylthio group, and a t-butylthio group.
- Examples of the halogen atom include fluorine, chlorine, and bromine.
- Examples of the aryl or heteroaryl group having a substituent include a 2-methylphenyl group, a 3-methylphenyl group, a 4-methylphenyl group, a 2-ethylphenyl group, a 3-ethylphenyl group, a 4-ethylphenyl group, and a 2-propylphenyl.
- examples of the substituent represented by R 2 include a hydroxyl group, a mercapto group, an alkoxy group having 1 to 8 carbon atoms, and an alkoxycarbonyl group having 2 to 8 carbon atoms.
- Examples of the above-mentioned C 1 to C 8 alkoxy group include formyloxy group, acetyloxy group, propionyloxy group, butyraloxy group and penyoxyloxy group. And a hexanoyloxy group, a heptanoyloxy group, an octanoyloxy group and a benzoyloxy group.
- alkoxycarbonyloxy group having 2 to 8 carbon atoms examples include, for example, methoxycarbonyloxy group, X-toxoxycarbonyloxy group, propoxycarponoxy group, butoxycarbonyloxy group, pentyloxycarponoxy group, and hexyloxy group.
- X is NR 3 , an oxygen atom, or a sulfur atom, wherein R 3 is a hydrogen atom or an alkyl group having 1 to 3 carbon atoms. , Methyl, ethyl, n-propyl, isopropyl and the like.
- the 5- or 6-membered monocyclic aromatic hetero ring containing one or two hetero atoms selected from a nitrogen atom, an oxygen atom or a sulfur atom, a thiophene ring or a furan ring A pyrrole ring, a thiazole ring, an isoxazole ring, an oxazole ring, a pyrazole ring, an imidazole ring, a pyridine ring, a pyrazine ring, a pyrimidine ring, or a pyridazine ring.
- Condensed bicyclic aromatic heterocyclic rings containing one or two hetero atoms include benzothiophene ring, benzofuran ring, indole ring, benzothiazole ring, benzoxazole ring, benzimidazole ring, quinoline ring And isoquinoline rings.
- the above-mentioned Y may be unsubstituted or partially substituted by a substituent.
- Preferred examples of Y include a naphthylene ring, a thiophene ring, a pyridine ring and a pyrazine ring, and these rings may be unsubstituted or partially substituted by a substituent.
- Y when Y is a pyridine ring, it may be substituted at any position of the pyridine ring with 1 to 4 substituents, and when Y is a pyrazine ring, 1 to 3 substituents May be substituted at any position of the pyrazine ring.
- the respective substituents When Y is substituted with two or more substituents, the respective substituents may be the same or different.
- the substituent of Y is an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms.
- the alkylthio group having 1 to 4 carbon atoms include a methylthio group, an ethylthio group, an propylthio group, a 2-propylthio group, a topylthio group, a 2-butylthio group, and a t-butylthio group.
- the halogen atom include fluorine, chlorine, and bromine. .
- Examples of the substituted Y include 2-methyl-naphthyl group, 3-methyl-1-naphthyl group, 4-methyl-naphthyl group, 5-methyl-1-naphthyl group, and 6-methyl-1-naphthyl group.
- 2-naphthyl group 5_chloro mouth-2-naphthyl group, 6-chloro mouth-2-naphthyl group, 7-chloro mouth-2-naphthyl group, 8-chloro mouth-2-naphthyl group, 2-fluoro- Naphthyl, 3-fluoro-1-naphthyl, 4-fluoro-1-naphthyl, 5-fluoro-1-naphthyl, 6-fluoro-naphthyl, 7-fluoro-1-naphthyl, 8 -Fluoro-1-naphthyl group, 1-fluoro mouth-2-naphthyl group, 3_fluoro-2-naphthyl group, 4-fluoro-2-naphthyl group, 5-fluoro-2-naphthyl group, 6-fluoro- 2-naphthyl group,
- 3-dimethylamino-1-naphthyl 4-dimethylamino-naphthyl, 5-dimethylamino-1-naphthyl, 6-dimethylamino-1-naphthyl, 7-dimethylamino-1-naphthyl, 8-dimethylamino-1 -Naphthyl group, 1-dimethylamino-2-naphthyl group, 3-dimethylamino-2-naphthyl group, 4-dimethylamino-2-naphthyl group, 5-dimethylamino-2-naphthyl group, 6-dimethylamino-2-naphthyl Group, 7-dimethylamino-2-naphthyl group, 8-dimethylamino-2-naphthyl group, 3-methyl-2-thenyl group, 4-methyl-2-thenyl group, 5-methyl
- 6-dimethylamino-'2-pyridyl group 2-dimethylamino-4-pyridyl group, 3-dimethylamino-4-pyridyl group, 5-dimethylamino-4-pyridyl group, 6-dimethylamino-4-pyridyl group, 2 -(1-pyrrolidinyl) -3-pyridyl group, 4- (topyrrolidinyl) -3-pyridyl group, 5- (topyrrolidinyl) -3-pyridyl group, 6- (topyrrolidinyl) -3-pyridyl group,
- X is more preferably an NH or an oxygen atom. Particularly, NH is preferable.
- R 1 is more preferably an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, or an alkynyl group having 2 to 6 carbon atoms, for example, a methyl group.
- Ethyl, propyl isopropyl, butyl, 2-butyl, pentyl, 2-pentyl, hexyl, 2-hexyl, vinyl, probenyl, butenyl, petite And a pentenyl group.
- alkyl groups having 3 to 5 carbon atoms alkenyl groups having 3 to 5 carbon atoms, alkynyl groups having 3 to 5 carbon atoms, specifically, propyl group, isopropyl group, butyl group, 2-butyl group, pentyl Groups, 2-pentyl group, propenyl group, butenyl group, butynyl group, pentenyl group and the like are more preferable, and propyl group, butyl group and pentyl group are particularly preferable.
- R 2 in the general formula (I) includes, for example, a hydroxyl group, an acetyloxy group, a propionyloxy group, a methoxycarbonyloxy group, an ethoxycarponyloxy group, a propoxycarbonyloxy group, a butoxycarponyloxy group.
- a hydroxyl group, a methoxycarbonyloxy group, and an ethoxycarbonyloxy group are preferable.
- Y in the general formula (I) includes a substituted or unsubstituted pyridine ring (2-pyridyl, 3-pyridyl, 4-pyridyl) and a pyrazine ring (2-pyrazinyl, 3-pyrazinyl). Particularly, a 3-pyridyl group is preferable.
- Examples of Y having a more preferable substituent include, for example, 2-methyl-3-pyridyl, 6-methyl-3-pyridyl, 2-ethyl-3-pyridyl, and 6-ethyl-3-pyridyl Group, 2-methoxy-3-pyridyl group, 6-methoxy-3-pyridyl group, 2-ethoxy-3-pyridyl group, 6-ethoxy-3-pyridyl group, 2-chloro-3-pyridyl group, 6 _______________ 3-pyridyl group, 6-dimethylamino-3-pyridyl group, 6- (topyrrolidinyl) -3-pyridyl group, 6-piberidino-3-pyridyl group, 6-morpholino-3-pyridyl group, 6 -Methylthio-3_pyridyl group, 5,6-dimethyl-3-pyridyl group, 5,6-dimethoxy-3-pyridy
- Methoxy-3-pyridyl group, 6-ethoxy-3-pyridyl group, 6-chloro-3-pyridyl group, 6- (1-pyrrolidinyl) -3-pyridyl group, 6-morpholino-3-pyridyl group, 2 -Methyl-3-pyridyl, 2-methoxy-3-pyridyl and 2-chloro-3-pyridyl are preferred.
- the compounds specifically included in the present invention include, for example, the following compounds
- the ester undergoes metabolism in the living body, and becomes a compound in which R 2 as the active substance is a hydroxyl group.
- the compound represented by the general formula (I) and its tautomer are chemically equivalent, and the adenine derivative of the present invention includes the tautomer.
- R 2 is a hydroxyl group
- the compound represented by the general formula (I) is represented by the general formula (II):
- an aprotic solvent such as dimethylformamide, dimethylsulfoxide, tetrahydrofuran, 1,4-dioxane or the like can be used, and the reaction can be carried out at a temperature from room temperature to the reflux temperature of the solvent.
- Bases include tertiary amines such as triethylamine, diisopropylethylamine, and 4-dimethylaminopyridine; solvents include aprotic solvents such as tetrahydrofuran, 1,4-dioxane, and diglyme; and propanol and butanol.
- An alcohol-based solvent can be used, or the reaction can be performed without a solvent. The reaction can be performed at a temperature ranging from 50 ° C to the reflux temperature of the solvent.
- 2-substituted compound (VI) is synthesized by reacting compound (V) with corresponding R 1 -0H or R 1 -SH in the presence of a base.
- Alkali metals such as sodium and potassium, alkali metal hydrides such as sodium hydride can be used as the base, and dimethylformamide, dimethylsulfoxide, tetrahydrofuran, 1,4-dioxane can be used as the solvent.
- the reaction can be performed using an aprotic solvent such as diglyme, or without a solvent. The reaction can be carried out at a temperature ranging from 50 ° C to the reflux temperature of the solvent.
- compound (VI) In the step of producing compound (VI) from compound (IV), first, a 2-substituted compound (V ′) is synthesized, and then the 2-substituted compound (V) and Y-CH 2 _Hal (wherein , Y has the same meaning as in formula ( ⁇ ), and Hal represents a halogen atom.) To obtain compound (VI).
- Compound (VI I) can be synthesized by reacting compound (VI) with bromine.
- a halogen-based solvent such as carbon tetrachloride, dichloromethane, and chloroform, acetic acid and the like can be used. The reaction can be carried out at a temperature between 0 ° C and the reflux temperature of the solvent.
- reaction aid such as sodium acetate may be added.
- Compound (IX) can be synthesized by hydrolyzing compound (VII) under acidic conditions.
- As the acid hydrochloric acid, hydrobromic acid and the like can be used.
- the reaction can be performed at a temperature ranging from 50 ° C to the reflux temperature of the solvent.
- (IX) can be obtained by reacting compound (VII) with sodium methoxide to give compound (VIII), followed by acid treatment and demethylation.
- Compound (X) can be synthesized by reacting compound (VII) with sodium hydrosulfide (sodium hydrogen sulfide).
- Solvents are ethanol, propanol, bushanol Any alcoholic solvent can be used. The reaction can be performed at a temperature ranging from 50 ° C to the reflux temperature of the solvent.
- Compound (XI) can be obtained by reacting compound (IX) with acyl chloride or chloroformate corresponding to R 2 in the presence of a base.
- a base such as triethylamine, diisopropylethylamine, and 4-dimethylaminopyridine can be used as the base, and aprotic solvents such as tetrahydrofuran, 1,4-dioxane, and dichloromethane can be used as the solvent.
- the reaction can be performed at a temperature ranging from 0 ° C. to the reflux temperature of the solvent (wherein R 4 represents an alkyl group having 1 to 7 carbon atoms or an alkoxy group having 1 to 7 carbon atoms).
- the adenine derivative of the present invention obtained as described above includes sodium salt, potassium salt, calcium salt, hydrochloride, hydrobromide, sulfate, nitrate, acetate, methanesulfonate, and toluenesulfonic acid. It can also be used as a pharmaceutically acceptable salt such as salt, citrate, fumarate, maleate and the like.
- the adenine derivative of the present invention is useful as a therapeutic drug for viral diseases such as hepatitis B and C, AIDS, cancer diseases, and diseases caused by type 2-helper T cells. It can be used in various dosage forms including oral preparations such as tablets, capsules and powders, as well as injections and external preparations.
- a substance selected from the group consisting of a compound represented by the general formula (I), a tautomer thereof, and a pharmaceutically acceptable salt thereof can be used. Hydrates or solvates thereof may be used. Two or more of these substances may be used in appropriate combination.
- the substance itself selected from these groups may be administered as the medicament of the present invention. Usually, however, a form of a pharmaceutical composition containing the above-mentioned substance as an active ingredient and a pharmaceutically acceptable additive for a pharmaceutical preparation is used. It is desirable to administer
- compositions for application to living organisms are prepared by mixing the above-mentioned substance as an active ingredient with one or more pharmaceutically acceptable additives for pharmaceutical preparations, and according to a general-purpose preparation method in the field of pharmacy. It can be easily manufactured.
- the administration route of the medicament of the present invention is not particularly limited, but it is desirable to appropriately select the most effective route for treatment and / or prevention.
- Pharmaceutical compositions suitable for oral administration include, for example, capsules, powders, tablets, granules, fine granules, syrups, solutions, suspensions and the like.
- inhalants for example, inhalants, sprays, rectal administration, injections, drops, ointments, creams, transdermal absorbers, transmucosal absorbers, eye drops, nasal drops, ear drops, tapes And a patch, but the form of the medicament of the present invention is not limited to these.
- liquid preparations such as emulsions and syrups include water; saccharides such as sucrose, sorbitol, fructose; glycols such as polyethylene glycol and propylene glycol; sesame oil and olive oil And oils such as soybean oil; preservatives such as P-hydroxybenzoic acid esters; and additives for pharmaceutical preparations such as flappers such as strobe flavor and peppermint.
- Solid preparations such as capsules, tablets, powders, and granules include excipients such as lactose, butu-sugar, sucrose, mannitol; disintegrants such as starch and sodium alginate; Lubricants; binders such as polyvinyl alcohol, hydroxypropyl cellulose, and gelatin; surfactants such as fatty acid esters; and plasticizers such as glycerin.
- excipients such as lactose, butu-sugar, sucrose, mannitol
- disintegrants such as starch and sodium alginate
- Lubricants such as polyvinyl alcohol, hydroxypropyl cellulose, and gelatin
- surfactants such as fatty acid esters
- plasticizers such as glycerin.
- compositions suitable for parenteral administration include those in the form of injections, drops, eye drops, etc.
- Liquid preparations can be prepared preferably as sterile isotonic liquid preparations.
- an injection can be prepared using an aqueous medium consisting of a salt solution, a glucose solution, or a mixture of saline and pudose solution.
- Rectal preparations can be prepared usually in the form of suppositories, using carriers such as cocoa butter, hydrogenated fats and hydrogenated carboxylic acids.
- a non-irritating carrier which disperses the above-mentioned substance as an active ingredient as fine particles to facilitate absorption can be used.
- Such carriers include, for example, lactose, glycerin and the like, and the form of the preparation can be selected from aerosol, dry powder and the like.
- the diluents, fragrances, preservatives, excipients, disintegrants, lubricants, binders, surfactants, plasticizers and the like exemplified for the oral preparations
- One or two or more pharmaceutical additives selected from the following can be used as appropriate.
- the pharmaceutical additives used for the production of the medicament of the present invention are not limited to those described above, and any additives that can be used by those skilled in the art may be used.
- the dose of the adenine derivative of the present invention is appropriately determined according to the sex, age, body weight, type of disease, symptom, etc. of the patient, but is generally in the range of 0.001 to 100 mg / kg per day. Preferably, it can be administered in a single dose or in divided doses in the range of 0.01 to 10 mg / kg.
- FIG. 1 is a graph showing the results of a drug efficacy evaluation test of the compound of the present invention in a rat eosinophil infiltration model.
- FIG. 2 is a graph showing the results of a drug efficacy evaluation test of the compound of the present invention in a mouse active skin anaphylaxis model.
- FIG. 3 is a diagram showing the results of the antitumor effect test described in Example 65.
- the tumor volume of each of the compound of Example 27 and mouse interferon was compared with that of the vehicle (control group).
- FIG. 4 is a view showing the results of an antitumor effect (metastasis suppressing effect) test described in Example 66.
- the wet weight of each lymph node was compared for each administration group of the vehicle (control group), mouse interferon ⁇ and the compound of Example 27.
- Example 1 2_-butoxy-9- (6-cloth-3-pyridylmethyl) -8-hydroxyadenine
- the compound obtained in Reference Example 3 (1.26 g, 3.47) was added to concentrated hydrochloric acid (70 mL). Then, the mixture was reacted at room temperature for 2 hours. After the reaction solution was concentrated under reduced pressure, water (130 mL) was added to the residue, and the mixture was neutralized with a 5N aqueous sodium hydroxide solution under ice-cooling. The precipitated crystals were collected by filtration and dried to obtain 1.20 g of the title compound as white powdery crystals (yield: 99%).
- Example 2 2_butoxy-8-hydroxy-9- (6-methoxy-3-pyridylmethyl) adenine
- the title compound was obtained in the same manner as in Example 1 using the corresponding starting materials.
- Example 3 2-butoxy-9- (6-ethoxy-3-pyridylmethyl) -8-hydroxyadenine The title compound was obtained in the same manner as in Example 1 using the corresponding starting materials.
- Example 5 2_-butoxy-9- (2-cyclohex-3-pyridylmethyl) -8-hydroxyadenine
- the title compound was obtained in the same manner as in Example 1 using the corresponding starting materials.
- Example 6 2-butoxy-8-hydroxy-9- (2-methoxy-3-pyridylmethyl) adenine The title compound was obtained in the same manner as in Example 1 using the corresponding starting materials.
- (4 mL) Concentrated hydrochloric acid (4 mL) was added to the suspension, and the mixture was reacted at 70 ° C for 9 hours. After the reaction solution was concentrated under reduced pressure, water (30 mL) was added to the residue under ice-cooling, and the mixture was neutralized with a 1N aqueous sodium hydroxide solution. After the precipitated solid was collected by filtration, the crude crystals were purified by silica gel column chromatography (methylene chloride: methanol 25: 1) to give 45 mg of the title compound as white powdery crystals (yield: 35).
- Example 13 Using the compound obtained in Example 1 and pyrrolidine, the title compound was obtained in the same manner as in Example 13.
- Example 13 The title compound was obtained in the same manner as in Example 13 using the compound obtained in Example 1 and morpholine.
- Example 13 The title compound was obtained in the same manner as in Example 13 using the compound obtained in Example 1 and a 40% aqueous dimethylamine solution.
- the title compound was obtained in the same manner as in Example 13 using the compound obtained in Example 17 and a 40% aqueous dimethylamine solution.
- Example 25 2_butoxy-8-hydroxy-9- (6-methyl-3-pyridylmethyl) adenine The title compound was obtained in the same manner as in Example 1 using the corresponding starting materials.
- Example 26 2-butoxy-8-hydroxy-9- (2-methyl-3-pyridylmethyl) adenine The title compound was obtained in the same manner as in Example 1 using the corresponding starting materials.
- Example 31 8-Hydroxy-2- (2-methoxy) ethoxy-9- (3-pyridylmethyl) adenyl
- the title compound was obtained in a similar manner to Example 1 using the corresponding starting material.
- Example 33 2-Butylamino-8-ethoxycarponyloxy-9- (6-methoxy-3-pyridylmethyl) adenine
- a methylene chloride solution 15 mL
- the compound obtained in Example 19 200 mg, 0.58 acetylol
- triethylamine 100 l, 0.75 melamine ol
- ethyl ethyl chloroformate 67 (il, 0.70 mmol)
- Dimethylaminopyridine (20 nig, 0.17 marl) was sequentially added and reacted at room temperature for 15 hours. Water was added to the reaction solution to extract an organic layer.
- Example 33 The title compound was obtained in the same manner as in Example 33, using the compound obtained in Example 17 and ethyl ethyl chloroformate.
- Example 19 Using the compound obtained in Example 19 and isopropyl chloroformate, the title compound was obtained in the same manner as in Example 33.
- Example 36 2-Butylamino-9- (6-kuguchi-3-pyridylmethyl) -8-isopropoxy carbonyloxyadenine
- the title compound was obtained in the same manner as in Example 33, using the compound obtained in Example 17 and isopropyl chloroformate.
- Example 33 The title compound was obtained in the same manner as in Example 33, using the compound obtained in Example 2 and ethyl ethyl chloroformate.
- Example 33 The title compound was obtained in the same manner as in Example 33, using the compound obtained in Example 1 and ethyl ethyl chloroformate.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60228229T DE60228229D1 (de) | 2001-04-17 | 2002-04-15 | Neue adeninderivate |
CA2444130A CA2444130C (en) | 2001-04-17 | 2002-04-15 | Adenine derivatives |
US10/474,199 US7157465B2 (en) | 2001-04-17 | 2002-04-15 | Adenine derivatives |
KR1020037013459A KR100892614B1 (ko) | 2001-04-17 | 2002-04-15 | 신규 아데닌 유도체 |
EP02717152A EP1386923B1 (en) | 2001-04-17 | 2002-04-15 | Novel adenine derivatives |
JP2002583432A JP4331944B2 (ja) | 2001-04-17 | 2002-04-15 | 新規アデニン誘導体 |
US11/582,452 US7521454B2 (en) | 2001-04-17 | 2006-10-18 | Adenine derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001118232 | 2001-04-17 | ||
JP2001-118232 | 2001-04-17 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10474199 A-371-Of-International | 2002-04-15 | ||
US11/582,452 Division US7521454B2 (en) | 2001-04-17 | 2006-10-18 | Adenine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002085905A1 true WO2002085905A1 (fr) | 2002-10-31 |
Family
ID=18968657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/003727 WO2002085905A1 (fr) | 2001-04-17 | 2002-04-15 | Nouveaux derives d'adenine |
Country Status (11)
Country | Link |
---|---|
US (2) | US7157465B2 (ja) |
EP (1) | EP1386923B1 (ja) |
JP (1) | JP4331944B2 (ja) |
KR (1) | KR100892614B1 (ja) |
CN (1) | CN1250548C (ja) |
AT (1) | ATE404561T1 (ja) |
CA (1) | CA2444130C (ja) |
DE (1) | DE60228229D1 (ja) |
ES (1) | ES2314042T3 (ja) |
TW (1) | TWI331150B (ja) |
WO (1) | WO2002085905A1 (ja) |
Cited By (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1550662A1 (en) * | 2002-09-27 | 2005-07-06 | Sumitomo Pharmaceuticals Company, Limited | Novel adenine compound and use thereof |
US7129244B2 (en) | 2003-09-18 | 2006-10-31 | Conforma Therapeutics Corporation | Triazolopyrimidines and related analogs as HSP90-inhibitors |
WO2007034917A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規なアデニン化合物 |
WO2007034817A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
WO2007060918A1 (ja) | 2005-11-24 | 2007-05-31 | Dainippon Sumitomo Pharma Co., Ltd. | 新規なメモリーctl誘導増強剤 |
US7241890B2 (en) | 2001-10-30 | 2007-07-10 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
US7427629B2 (en) | 2002-08-15 | 2008-09-23 | 3M Innovative Properties Company | Immunostimulatory compositions and methods of stimulating an immune response |
WO2008114817A1 (ja) | 2007-03-20 | 2008-09-25 | Dainippon Sumitomo Pharma Co., Ltd. | 新規なアデニン化合物 |
JP2009507036A (ja) * | 2005-09-02 | 2009-02-19 | ファイザー・インク | ヒドロキシ置換1h−イミダゾピリジンおよび方法 |
WO2010033074A1 (en) * | 2008-09-18 | 2010-03-25 | Astrazeneca Ab | Use of a tlr7 agonist for the treatment of cancer |
US7696159B2 (en) | 2003-03-25 | 2010-04-13 | Graceway Pharmaceuticals, Llc | Treatment for basal cell carcinoma |
WO2010063865A1 (es) | 2008-12-03 | 2010-06-10 | Proyecto De Biomedicina Cima, S.L. | Uso de modulinas solubles en fenol para el desarrollo de vacunas |
WO2010149745A1 (en) | 2009-06-24 | 2010-12-29 | Glaxosmithkline Biologicals S.A. | Recombinant rsv antigens |
WO2010149743A2 (en) | 2009-06-24 | 2010-12-29 | Id Biomedical Corporation Of Quebec | Vaccine |
US7923560B2 (en) | 2003-04-10 | 2011-04-12 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
WO2011051445A1 (en) | 2009-10-30 | 2011-05-05 | Glaxosmithkline Biologicals S.A. | Process for preparing an influenza seed virus for vaccine manufacture |
EP2357184A1 (en) | 2006-03-23 | 2011-08-17 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
WO2011101332A1 (en) | 2010-02-16 | 2011-08-25 | Proyecto De Biomedicina Cima, S.L. | Compositions based on the fibronectin extracellular domain a for the treatment of melanoma |
US8044056B2 (en) | 2007-03-20 | 2011-10-25 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine compound |
WO2011151431A1 (en) | 2010-06-03 | 2011-12-08 | Glaxosmithkline Biologicals S.A. | Oral vaccine comprising an antigen and a toll-like receptor agonist |
US8110582B2 (en) | 2003-03-04 | 2012-02-07 | 3M Innovative Properties Company | Prophylactic treatment of UV-induced epidermal neoplasia |
JP2012503655A (ja) * | 2008-09-26 | 2012-02-09 | インテリカイン, インコーポレイテッド | 複素環キナーゼ阻害剤 |
US8138172B2 (en) | 2006-07-05 | 2012-03-20 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of TLR7 |
EP2433648A2 (en) | 2006-10-12 | 2012-03-28 | GlaxoSmithKline Biologicals S.A. | Vaccine comprising an oil in water emulsion adjuvant |
EP2455101A2 (en) | 2007-04-20 | 2012-05-23 | GlaxoSmithKline Biologicals S.A. | Influenza vaccine with oil-in-water emulsion adjuvant |
EP2505640A1 (en) | 2011-03-29 | 2012-10-03 | Neo Virnatech, S.L. | Vaccine compositions for birnavirus-borne diseases |
EP2572714A1 (en) | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
US8426457B2 (en) | 2003-03-13 | 2013-04-23 | Medicis Pharmaceutical Corporation | Methods of improving skin quality |
WO2013072519A1 (en) | 2011-11-20 | 2013-05-23 | Glaxosmithkline Biologicals S.A. | Vaccine |
EP2612680A1 (en) | 2008-04-16 | 2013-07-10 | GlaxoSmithKline Biologicals SA | Vaccine |
EP2614709A1 (en) | 2005-07-18 | 2013-07-17 | Novartis AG | Small animal model for HCV replication |
US8507507B2 (en) | 2009-10-22 | 2013-08-13 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
WO2013139744A1 (en) | 2012-03-18 | 2013-09-26 | Glaxosmithkline Biologicals S.A. | Method of vaccination against human papillomavirus |
US8575180B2 (en) | 2004-03-26 | 2013-11-05 | Astrazeneca Aktiebolag | 9-substituted 8-oxoadenine compound |
WO2014024024A1 (en) | 2012-08-06 | 2014-02-13 | Glaxosmithkline Biologicals S.A. | Method for eliciting in infants an immune response against rsv |
WO2014024026A1 (en) | 2012-08-06 | 2014-02-13 | Glaxosmithkline Biologicals S.A. | Method for eliciting in infants an immune response against rsv and b. pertussis |
US8673907B2 (en) | 2007-12-17 | 2014-03-18 | Astrazeneca Ab | Pharmaceutically acceptable salts of methyl (3-{ [[3-(6-amino- 2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl) propyl] (3-morpholin-4-ylpropyl) amino] methyl }phenyl) acetate and their use in therapy |
US8691837B2 (en) | 2003-11-25 | 2014-04-08 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
US8871782B2 (en) | 2003-10-03 | 2014-10-28 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
US8895570B2 (en) | 2010-12-17 | 2014-11-25 | Astrazeneca Ab | Purine derivatives |
US8940755B2 (en) | 2003-12-02 | 2015-01-27 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
US9045472B2 (en) | 2010-12-16 | 2015-06-02 | Astrazeneca Ab | Imidazoquinoline compounds |
US9050319B2 (en) | 2010-04-30 | 2015-06-09 | Telormedix, Sa | Phospholipid drug analogs |
US9066940B2 (en) | 2009-02-06 | 2015-06-30 | Telormedix, Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
US9173935B2 (en) | 2010-04-30 | 2015-11-03 | Telormedix Sa | Phospholipid drug analogs |
EP2952893A1 (en) | 2014-06-04 | 2015-12-09 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Method for detecting antibody-secreting B cells specific for HLA |
US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
US9376398B2 (en) | 2012-05-18 | 2016-06-28 | Sumitomo Dainippon Pharma Co., Ltd | Carboxylic acid compounds |
WO2016140702A1 (en) | 2015-03-03 | 2016-09-09 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Serivces | Display platform from bacterial spore coat proteins |
EP3109258A1 (en) | 2007-12-24 | 2016-12-28 | ID Biomedical Corporation of Quebec | Recombinant rsv antigens |
WO2017056494A1 (en) | 2015-09-29 | 2017-04-06 | Sumitomo Dainippon Pharma Co., Ltd. | Adenine conjugate compounds and their use as vaccine adjuvants |
WO2018109220A2 (en) | 2016-12-16 | 2018-06-21 | Institute For Research In Biomedicine | Novel recombinant prefusion rsv f proteins and uses thereof |
WO2018162450A1 (en) | 2017-03-06 | 2018-09-13 | Fundación Para La Investigación Médica Aplicada | New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells |
WO2018181420A1 (ja) | 2017-03-29 | 2018-10-04 | 大日本住友製薬株式会社 | ワクチンアジュバント製剤 |
WO2018193063A2 (en) | 2017-04-19 | 2018-10-25 | Institute For Research In Biomedicine | Novel malaria vaccines and antibodies binding to plasmodium sporozoites |
EP3492097A1 (en) | 2013-08-05 | 2019-06-05 | GlaxoSmithKline Biologicals S.A. | Combination immunogenic compositions |
WO2019124500A1 (ja) | 2017-12-21 | 2019-06-27 | 大日本住友製薬株式会社 | Tlr7アゴニストを含む併用薬 |
EP3556353A2 (en) | 2014-02-25 | 2019-10-23 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
EP3581201A1 (en) | 2018-06-15 | 2019-12-18 | GlaxoSmithKline Biologicals S.A. | Escherichia coli o157:h7 proteins and uses thereof |
WO2020022272A1 (ja) | 2018-07-23 | 2020-01-30 | 公益財団法人ヒューマンサイエンス振興財団 | インフルエンザワクチンを含む組成物 |
EP3608332A1 (en) | 2013-03-15 | 2020-02-12 | GlaxoSmithKline Biologicals S.A. | Vaccine against human rhinovirus |
EP3888676A1 (en) | 2014-06-13 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Immunogenic combinations |
WO2022117595A2 (en) | 2020-12-02 | 2022-06-09 | Glaxosmithkline Biologicals Sa | Novel antigens |
US11420970B1 (en) | 2019-08-14 | 2022-08-23 | Novartis Ag | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents |
US11629181B2 (en) | 2009-07-15 | 2023-04-18 | Glaxosmithkline Biologicals Sa | RSV F protein compositions and methods for making same |
WO2023114727A1 (en) | 2021-12-13 | 2023-06-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bacteriophage lambda-vaccine system |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1850850A4 (en) * | 2000-12-08 | 2011-06-15 | 3M Innovative Properties Co | COMPOSITIONS AND METHOD FOR TARGETED ADMINISTRATION OF IMMUNE RESPONSE MODIFICATORS |
US7321033B2 (en) | 2001-11-27 | 2008-01-22 | Anadys Pharmaceuticals, Inc. | 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof |
AU2002357295A1 (en) * | 2001-12-18 | 2003-06-30 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
GB0215293D0 (en) | 2002-07-03 | 2002-08-14 | Rega Foundation | Viral inhibitors |
JP2007502288A (ja) | 2003-08-12 | 2007-02-08 | スリーエム イノベイティブ プロパティズ カンパニー | オキシム置換イミダゾ含有化合物 |
KR101106812B1 (ko) | 2003-08-27 | 2012-01-19 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 아릴옥시 및 아릴알킬렌옥시 치환된 이미다조퀴놀린 |
CA2537763A1 (en) | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for cd5+ b cell lymphoma |
DE602004026891D1 (de) | 2003-09-05 | 2010-06-10 | Anadys Pharmaceuticals Inc | Tlr7-liganden zur behandlung von hepatitis c |
US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
JP2007511535A (ja) | 2003-11-14 | 2007-05-10 | スリーエム イノベイティブ プロパティズ カンパニー | ヒドロキシルアミン置換イミダゾ環化合物 |
US7897767B2 (en) | 2003-11-14 | 2011-03-01 | 3M Innovative Properties Company | Oxime substituted imidazoquinolines |
US20050226878A1 (en) * | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
EP1706403B9 (en) | 2003-12-22 | 2012-07-25 | K.U.Leuven Research & Development | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment |
US8802853B2 (en) | 2003-12-29 | 2014-08-12 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
AU2004312508A1 (en) | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides |
TW200612932A (en) | 2004-03-24 | 2006-05-01 | 3M Innovative Properties Co | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
WO2005092892A1 (ja) * | 2004-03-26 | 2005-10-06 | Dainippon Sumitomo Pharma Co., Ltd. | 8−オキソアデニン化合物 |
WO2005123080A2 (en) | 2004-06-15 | 2005-12-29 | 3M Innovative Properties Company | Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
WO2006038923A2 (en) | 2004-06-18 | 2006-04-13 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
WO2006009832A1 (en) * | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
US7915281B2 (en) | 2004-06-18 | 2011-03-29 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method |
WO2006009826A1 (en) | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
US20090208456A1 (en) | 2004-07-27 | 2009-08-20 | Gilead Sciences, Inc. | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation |
WO2006026470A2 (en) * | 2004-08-27 | 2006-03-09 | 3M Innovative Properties Company | Hiv immunostimulatory compositions |
JP5303149B2 (ja) | 2004-12-17 | 2013-10-02 | アナディス ファーマシューティカルズ インク | 3,5−二置換及び3,5,7−三置換−3H−オキサゾロ及び3H−チアゾロ[4,5−d]ピリミジン−2−オン化合物及びそのプロドラッグ |
DE602005013580D1 (de) | 2004-12-21 | 2009-05-07 | Leuven K U Res & Dev | Imidazoä4,5-cüpyridinverbindung und verfahren zur antiviralen behandlung |
JP5543068B2 (ja) | 2004-12-30 | 2014-07-09 | スリーエム イノベイティブ プロパティズ カンパニー | キラル縮合[1,2]イミダゾ[4,5−c]環状化合物 |
ES2392648T3 (es) | 2004-12-30 | 2012-12-12 | 3M Innovative Properties Company | Compuestos quirales sustituidos que contienen un núcleo 1,2-imidazo-4,5-c condensado |
CA2597587A1 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
JP2008535832A (ja) | 2005-04-01 | 2008-09-04 | コーリー ファーマシューティカル グループ,インコーポレイテッド | ピラゾロピリジン−1,4−ジアミン、およびそのアナログ |
WO2006107851A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
JP2008540396A (ja) | 2005-05-04 | 2008-11-20 | ファイザー・リミテッド | 癌およびc型肝炎などのウイルス感染を治療するためのトール様受容体調節薬としての2−アミド−6−アミノ−8−オキソプリン誘導体 |
JP2009504803A (ja) | 2005-08-22 | 2009-02-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Tlrアゴニスト |
TW200801003A (en) * | 2005-09-16 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
TW200745114A (en) * | 2005-09-22 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
EP1939200A4 (en) * | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
WO2007034881A1 (ja) * | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
WO2007034882A1 (ja) * | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
SG152296A1 (en) | 2005-11-21 | 2009-05-29 | Anadys Pharmaceuticals Inc | Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2- one |
WO2007142755A2 (en) * | 2006-05-31 | 2007-12-13 | The Regents Of The University Of California | Purine analogs |
KR101461604B1 (ko) | 2006-06-22 | 2014-11-18 | 애나디스 파마슈티칼스, 인코포레이티드 | 5-아미노-3-(3''-데옥시-β-D-리보퓨라노실)-티아졸로[4,5-d]파이리미딘-2,7-다이온의 프로드럭 |
DE602007004220D1 (de) | 2006-07-07 | 2010-02-25 | Leuven K U Res & Dev | Neue pyridazinverbindung und ihre verwendung |
WO2008008432A2 (en) | 2006-07-12 | 2008-01-17 | Coley Pharmaceutical Group, Inc. | Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods |
DE602007012881D1 (en) | 2006-07-18 | 2011-04-14 | Anadys Pharmaceuticals Inc | Carbonat- und carbamat-prodrugs von thiazolo ä4,5-dü-pyrimidinen |
TW200831105A (en) * | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
CN101790380B (zh) | 2007-02-07 | 2013-07-10 | 加利福尼亚大学董事会 | 合成tlr激动剂的缀合物及其应用 |
EP2139894B1 (en) * | 2007-03-19 | 2011-10-26 | AstraZeneca AB | 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators |
SI2132209T1 (sl) | 2007-03-19 | 2014-05-30 | Astrazeneca Ab | Spojine 9-substituiranega-8-okso-adenina, kot modulatorji Toll-like receptorja (TLR7) |
PL2155743T3 (pl) * | 2007-05-08 | 2013-01-31 | Astrazeneca Ab | Imidazochinoliny o właściwościach immunomodulacyjnych |
UA99466C2 (en) | 2007-07-06 | 2012-08-27 | Гилиад Сайенсиз, Инк. | Crystalline pyridazine compound |
PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
KR20100125245A (ko) | 2008-01-17 | 2010-11-30 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 아데닌 화합물의 제조 방법 |
WO2009091031A1 (ja) * | 2008-01-17 | 2009-07-23 | Dainippon Sumitomo Pharma Co., Ltd. | アデニン化合物の製造方法 |
CN102088974A (zh) * | 2008-02-07 | 2011-06-08 | 加利福尼亚大学校务委员会 | 用tlr7活化剂对膀胱疾病的治疗 |
ES2467108T3 (es) | 2008-12-09 | 2014-06-11 | Gilead Sciences, Inc. | Moduladores de receptores tipo toll |
BRPI1008383A2 (pt) * | 2009-02-11 | 2016-02-23 | Univ California | composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto |
UY32648A (es) | 2009-05-21 | 2010-12-31 | Astrazeneca Ab | Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades |
GB0908772D0 (en) * | 2009-05-21 | 2009-07-01 | Astrazeneca Ab | New salts 756 |
EP2507237A1 (en) * | 2009-12-03 | 2012-10-10 | Dainippon Sumitomo Pharma Co., Ltd. | Imidazoquinolines which act via toll - like receptors (tlr) |
US20110150836A1 (en) * | 2009-12-22 | 2011-06-23 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
EA201790024A1 (ru) | 2014-07-11 | 2017-07-31 | Джилид Сайэнс, Инк. | Модуляторы toll-подобных рецепторов для лечения вич |
EA201790369A1 (ru) | 2014-09-16 | 2017-10-31 | Джилид Сайэнс, Инк. | Твердые формы модулятора толл-подобного рецептора |
US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
JP2023512208A (ja) | 2020-01-27 | 2023-03-24 | ブリストル-マイヤーズ スクイブ カンパニー | トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物 |
CN115151546A (zh) | 2020-01-27 | 2022-10-04 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的C3-取代的1H-吡唑并[4,3-d]嘧啶化合物 |
EP4097100A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
JP2023512205A (ja) | 2020-01-27 | 2023-03-24 | ブリストル-マイヤーズ スクイブ カンパニー | トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物 |
EP4097105A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
US20230130516A1 (en) | 2020-01-27 | 2023-04-27 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
CN115210235A (zh) | 2020-01-27 | 2022-10-18 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
CN115643805A (zh) | 2020-01-27 | 2023-01-24 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
CN115151547A (zh) | 2020-01-27 | 2022-10-04 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
JP2024518998A (ja) * | 2021-05-13 | 2024-05-08 | プロメガ コーポレイション | Dna合成の生物発光による検出 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4816519B1 (ja) * | 1969-08-22 | 1973-05-22 | ||
JPH11193282A (ja) * | 1997-12-26 | 1999-07-21 | Sumitomo Pharmaceut Co Ltd | 複素環化合物 |
EP1035123A1 (en) * | 1997-11-28 | 2000-09-13 | Sumitomo Pharmaceuticals Company, Limited | Novel heterocyclic compounds |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US191086A (en) * | 1877-05-22 | Improvement in cattle-stalls | ||
US2705715A (en) * | 1952-10-29 | 1955-04-05 | American Cyanamid Co | Purine compounds and methods of preparing the same |
ZA848968B (en) | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
US4772606A (en) * | 1985-08-22 | 1988-09-20 | Warner-Lambert Company | Purine derivatives |
DE3517709A1 (de) * | 1985-01-05 | 1986-07-10 | Bayer Ag | Basische zubereitungen von chinoloncarbonsaeuren |
IL78643A0 (en) | 1985-05-02 | 1986-08-31 | Wellcome Found | Purine derivatives,their preparation and pharmaceutical compositions containing them |
JPH08165292A (ja) | 1993-10-07 | 1996-06-25 | Techno Res Kk | アデニン誘導体、その製造法及び用途 |
ES2232871T3 (es) | 1996-07-03 | 2005-06-01 | Sumitomo Pharmaceuticals Company, Limited | Nuevos derivados de purina. |
CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
AU2002357295A1 (en) * | 2001-12-18 | 2003-06-30 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
NZ539064A (en) * | 2002-09-27 | 2007-09-28 | Dainippon Sumitomo Pharma Co | Novel adenine compound and use thereof |
-
2002
- 2002-04-15 US US10/474,199 patent/US7157465B2/en not_active Expired - Fee Related
- 2002-04-15 WO PCT/JP2002/003727 patent/WO2002085905A1/ja active IP Right Grant
- 2002-04-15 EP EP02717152A patent/EP1386923B1/en not_active Expired - Lifetime
- 2002-04-15 ES ES02717152T patent/ES2314042T3/es not_active Expired - Lifetime
- 2002-04-15 AT AT02717152T patent/ATE404561T1/de not_active IP Right Cessation
- 2002-04-15 KR KR1020037013459A patent/KR100892614B1/ko not_active IP Right Cessation
- 2002-04-15 DE DE60228229T patent/DE60228229D1/de not_active Expired - Lifetime
- 2002-04-15 CA CA2444130A patent/CA2444130C/en not_active Expired - Fee Related
- 2002-04-15 CN CNB028113004A patent/CN1250548C/zh not_active Expired - Fee Related
- 2002-04-15 JP JP2002583432A patent/JP4331944B2/ja not_active Expired - Lifetime
- 2002-04-16 TW TW091107713A patent/TWI331150B/zh not_active IP Right Cessation
-
2006
- 2006-10-18 US US11/582,452 patent/US7521454B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4816519B1 (ja) * | 1969-08-22 | 1973-05-22 | ||
EP1035123A1 (en) * | 1997-11-28 | 2000-09-13 | Sumitomo Pharmaceuticals Company, Limited | Novel heterocyclic compounds |
JPH11193282A (ja) * | 1997-12-26 | 1999-07-21 | Sumitomo Pharmaceut Co Ltd | 複素環化合物 |
Cited By (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7241890B2 (en) | 2001-10-30 | 2007-07-10 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
US7427629B2 (en) | 2002-08-15 | 2008-09-23 | 3M Innovative Properties Company | Immunostimulatory compositions and methods of stimulating an immune response |
EP1550662A4 (en) * | 2002-09-27 | 2007-03-07 | Dainippon Sumitomo Pharma Co | NEW ADENINE COMPOUND AND ITS USE |
US8148371B2 (en) | 2002-09-27 | 2012-04-03 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine compound and use thereof |
US7754728B2 (en) | 2002-09-27 | 2010-07-13 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine compound and use thereof |
EP1550662A1 (en) * | 2002-09-27 | 2005-07-06 | Sumitomo Pharmaceuticals Company, Limited | Novel adenine compound and use thereof |
US10105426B2 (en) | 2002-12-30 | 2018-10-23 | Trustees Of Dartmouth College | Immunostimulatory combinations |
EP2572715A1 (en) | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
EP2572714A1 (en) | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
US8110582B2 (en) | 2003-03-04 | 2012-02-07 | 3M Innovative Properties Company | Prophylactic treatment of UV-induced epidermal neoplasia |
US8426457B2 (en) | 2003-03-13 | 2013-04-23 | Medicis Pharmaceutical Corporation | Methods of improving skin quality |
US8835394B2 (en) | 2003-03-25 | 2014-09-16 | Medicis Pharmaceutical Corporation | Treatment for basal cell carcinoma |
US7696159B2 (en) | 2003-03-25 | 2010-04-13 | Graceway Pharmaceuticals, Llc | Treatment for basal cell carcinoma |
US7923560B2 (en) | 2003-04-10 | 2011-04-12 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
US7138401B2 (en) | 2003-09-18 | 2006-11-21 | Conforma Therapeutics Corporation | 2-aminopurine analogs having HSP90-inhibiting activity |
US7129244B2 (en) | 2003-09-18 | 2006-10-31 | Conforma Therapeutics Corporation | Triazolopyrimidines and related analogs as HSP90-inhibitors |
US7138402B2 (en) | 2003-09-18 | 2006-11-21 | Conforma Therapeutics Corporation | Pyrrolopyrimidines and related analogs as HSP90-inhibitors |
US7148228B2 (en) | 2003-09-18 | 2006-12-12 | Conforma Therapeutics Corporation | Pyrazolopyrimidines and related analogs as HSP90-inhibitors |
US8871782B2 (en) | 2003-10-03 | 2014-10-28 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
US8691837B2 (en) | 2003-11-25 | 2014-04-08 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
US8940755B2 (en) | 2003-12-02 | 2015-01-27 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
US8969362B2 (en) | 2004-03-26 | 2015-03-03 | Astrazeneca Aktiebolag | 9-substituted 8-oxoadenine compound |
US8575180B2 (en) | 2004-03-26 | 2013-11-05 | Astrazeneca Aktiebolag | 9-substituted 8-oxoadenine compound |
US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
US10071156B2 (en) | 2005-02-04 | 2018-09-11 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
EP2614709A1 (en) | 2005-07-18 | 2013-07-17 | Novartis AG | Small animal model for HCV replication |
JP2009507036A (ja) * | 2005-09-02 | 2009-02-19 | ファイザー・インク | ヒドロキシ置換1h−イミダゾピリジンおよび方法 |
WO2007034817A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
WO2007034917A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規なアデニン化合物 |
WO2007060918A1 (ja) | 2005-11-24 | 2007-05-31 | Dainippon Sumitomo Pharma Co., Ltd. | 新規なメモリーctl誘導増強剤 |
EP2357184A1 (en) | 2006-03-23 | 2011-08-17 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
US8138172B2 (en) | 2006-07-05 | 2012-03-20 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of TLR7 |
EP2433648A2 (en) | 2006-10-12 | 2012-03-28 | GlaxoSmithKline Biologicals S.A. | Vaccine comprising an oil in water emulsion adjuvant |
JPWO2008114817A1 (ja) * | 2007-03-20 | 2010-07-08 | 大日本住友製薬株式会社 | 新規なアデニン化合物 |
WO2008114817A1 (ja) | 2007-03-20 | 2008-09-25 | Dainippon Sumitomo Pharma Co., Ltd. | 新規なアデニン化合物 |
US8044056B2 (en) | 2007-03-20 | 2011-10-25 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine compound |
EP2455101A2 (en) | 2007-04-20 | 2012-05-23 | GlaxoSmithKline Biologicals S.A. | Influenza vaccine with oil-in-water emulsion adjuvant |
US8673907B2 (en) | 2007-12-17 | 2014-03-18 | Astrazeneca Ab | Pharmaceutically acceptable salts of methyl (3-{ [[3-(6-amino- 2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl) propyl] (3-morpholin-4-ylpropyl) amino] methyl }phenyl) acetate and their use in therapy |
EP4206231A1 (en) | 2007-12-24 | 2023-07-05 | ID Biomedical Corporation of Quebec | Recombinant rsv antigens |
EP3508505A1 (en) | 2007-12-24 | 2019-07-10 | ID Biomedical Corporation of Quebec | Recombinant rsv antigens |
EP4219566A2 (en) | 2007-12-24 | 2023-08-02 | ID Biomedical Corporation of Quebec | Recombinant rsv antigens |
EP4108688A1 (en) | 2007-12-24 | 2022-12-28 | ID Biomedical Corporation of Quebec | Recombinant rsv antigens |
EP4108687A1 (en) | 2007-12-24 | 2022-12-28 | ID Biomedical Corporation of Quebec | Recombinant rsv antigens |
EP3109258A1 (en) | 2007-12-24 | 2016-12-28 | ID Biomedical Corporation of Quebec | Recombinant rsv antigens |
EP2612680A1 (en) | 2008-04-16 | 2013-07-10 | GlaxoSmithKline Biologicals SA | Vaccine |
WO2010033074A1 (en) * | 2008-09-18 | 2010-03-25 | Astrazeneca Ab | Use of a tlr7 agonist for the treatment of cancer |
JP2012503655A (ja) * | 2008-09-26 | 2012-02-09 | インテリカイン, インコーポレイテッド | 複素環キナーゼ阻害剤 |
WO2010063865A1 (es) | 2008-12-03 | 2010-06-10 | Proyecto De Biomedicina Cima, S.L. | Uso de modulinas solubles en fenol para el desarrollo de vacunas |
US9066940B2 (en) | 2009-02-06 | 2015-06-30 | Telormedix, Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
US9107919B2 (en) | 2009-02-06 | 2015-08-18 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
WO2010149743A2 (en) | 2009-06-24 | 2010-12-29 | Id Biomedical Corporation Of Quebec | Vaccine |
WO2010149745A1 (en) | 2009-06-24 | 2010-12-29 | Glaxosmithkline Biologicals S.A. | Recombinant rsv antigens |
US11629181B2 (en) | 2009-07-15 | 2023-04-18 | Glaxosmithkline Biologicals Sa | RSV F protein compositions and methods for making same |
US11827694B2 (en) | 2009-07-15 | 2023-11-28 | Glaxosmithkline Biologicals Sa | RSV F protein compositions and methods for making same |
US11655284B2 (en) | 2009-07-15 | 2023-05-23 | Glaxosmithkline Biologicals Sa | RSV F protein compositions and methods for making same |
US11820812B2 (en) | 2009-07-15 | 2023-11-21 | Glaxosmithkline Biologicals Sa | RSV F protein compositions and methods for making same |
US8962652B2 (en) | 2009-10-22 | 2015-02-24 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
US9161934B2 (en) | 2009-10-22 | 2015-10-20 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
US8507507B2 (en) | 2009-10-22 | 2013-08-13 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
WO2011051445A1 (en) | 2009-10-30 | 2011-05-05 | Glaxosmithkline Biologicals S.A. | Process for preparing an influenza seed virus for vaccine manufacture |
WO2011101332A1 (en) | 2010-02-16 | 2011-08-25 | Proyecto De Biomedicina Cima, S.L. | Compositions based on the fibronectin extracellular domain a for the treatment of melanoma |
US9050319B2 (en) | 2010-04-30 | 2015-06-09 | Telormedix, Sa | Phospholipid drug analogs |
US9180183B2 (en) | 2010-04-30 | 2015-11-10 | Telormedix Sa | Phospholipid drug analogs |
US9173936B2 (en) | 2010-04-30 | 2015-11-03 | Telormedix Sa | Phospholipid drug analogs |
US9173935B2 (en) | 2010-04-30 | 2015-11-03 | Telormedix Sa | Phospholipid drug analogs |
WO2011151431A1 (en) | 2010-06-03 | 2011-12-08 | Glaxosmithkline Biologicals S.A. | Oral vaccine comprising an antigen and a toll-like receptor agonist |
US9045472B2 (en) | 2010-12-16 | 2015-06-02 | Astrazeneca Ab | Imidazoquinoline compounds |
US8895570B2 (en) | 2010-12-17 | 2014-11-25 | Astrazeneca Ab | Purine derivatives |
WO2012131139A1 (es) | 2011-03-29 | 2012-10-04 | Neo Virnatech, S.L. | Composiciones de vacuna para enfermedades transmitidas por birnavirus |
EP2505640A1 (en) | 2011-03-29 | 2012-10-03 | Neo Virnatech, S.L. | Vaccine compositions for birnavirus-borne diseases |
WO2013072519A1 (en) | 2011-11-20 | 2013-05-23 | Glaxosmithkline Biologicals S.A. | Vaccine |
WO2013139744A1 (en) | 2012-03-18 | 2013-09-26 | Glaxosmithkline Biologicals S.A. | Method of vaccination against human papillomavirus |
US11299465B2 (en) | 2012-05-18 | 2022-04-12 | Sumitomo Dainippon Pharma Co., Ltd. | Carboxylic acid compounds |
US10562861B2 (en) | 2012-05-18 | 2020-02-18 | Sumitomo Dainippon Pharma Co., Ltd. | Carboxylic acid compounds |
US10150743B2 (en) | 2012-05-18 | 2018-12-11 | Sumitomo Dainippon Pharma Co., Ltd. | Carboxylic acid compounds |
US9376398B2 (en) | 2012-05-18 | 2016-06-28 | Sumitomo Dainippon Pharma Co., Ltd | Carboxylic acid compounds |
WO2014024026A1 (en) | 2012-08-06 | 2014-02-13 | Glaxosmithkline Biologicals S.A. | Method for eliciting in infants an immune response against rsv and b. pertussis |
EP3488865A1 (en) | 2012-08-06 | 2019-05-29 | GlaxoSmithKline Biologicals S.A. | Method for eliciting in infants an immune response against rsv and b. pertussis |
WO2014024024A1 (en) | 2012-08-06 | 2014-02-13 | Glaxosmithkline Biologicals S.A. | Method for eliciting in infants an immune response against rsv |
EP3608332A1 (en) | 2013-03-15 | 2020-02-12 | GlaxoSmithKline Biologicals S.A. | Vaccine against human rhinovirus |
EP3492097A1 (en) | 2013-08-05 | 2019-06-05 | GlaxoSmithKline Biologicals S.A. | Combination immunogenic compositions |
EP3556353A2 (en) | 2014-02-25 | 2019-10-23 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
EP2952893A1 (en) | 2014-06-04 | 2015-12-09 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Method for detecting antibody-secreting B cells specific for HLA |
US10527630B2 (en) | 2014-06-04 | 2020-01-07 | Institut D'investigació Biomèdica De Bellvitge (Idibell) | Method for detecting antibody-secreting B cells specific for HLA |
EP3888676A1 (en) | 2014-06-13 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Immunogenic combinations |
WO2016140702A1 (en) | 2015-03-03 | 2016-09-09 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Serivces | Display platform from bacterial spore coat proteins |
US10597397B2 (en) | 2015-09-29 | 2020-03-24 | Sumitomo Dainippon Pharma Co., Ltd. | Adenine conjugate compounds and their use as vaccine adjuvants |
WO2017056494A1 (en) | 2015-09-29 | 2017-04-06 | Sumitomo Dainippon Pharma Co., Ltd. | Adenine conjugate compounds and their use as vaccine adjuvants |
WO2018109220A2 (en) | 2016-12-16 | 2018-06-21 | Institute For Research In Biomedicine | Novel recombinant prefusion rsv f proteins and uses thereof |
WO2018162450A1 (en) | 2017-03-06 | 2018-09-13 | Fundación Para La Investigación Médica Aplicada | New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells |
WO2018181420A1 (ja) | 2017-03-29 | 2018-10-04 | 大日本住友製薬株式会社 | ワクチンアジュバント製剤 |
WO2018193063A2 (en) | 2017-04-19 | 2018-10-25 | Institute For Research In Biomedicine | Novel malaria vaccines and antibodies binding to plasmodium sporozoites |
WO2019124500A1 (ja) | 2017-12-21 | 2019-06-27 | 大日本住友製薬株式会社 | Tlr7アゴニストを含む併用薬 |
EP3581201A1 (en) | 2018-06-15 | 2019-12-18 | GlaxoSmithKline Biologicals S.A. | Escherichia coli o157:h7 proteins and uses thereof |
WO2019238757A1 (en) | 2018-06-15 | 2019-12-19 | Glaxosmithkline Biologicals Sa | Escherichia coli o157:h7 proteins and uses thereof |
WO2020022272A1 (ja) | 2018-07-23 | 2020-01-30 | 公益財団法人ヒューマンサイエンス振興財団 | インフルエンザワクチンを含む組成物 |
US11420970B1 (en) | 2019-08-14 | 2022-08-23 | Novartis Ag | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents |
WO2022117595A2 (en) | 2020-12-02 | 2022-06-09 | Glaxosmithkline Biologicals Sa | Novel antigens |
WO2023114727A1 (en) | 2021-12-13 | 2023-06-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bacteriophage lambda-vaccine system |
Also Published As
Publication number | Publication date |
---|---|
JP4331944B2 (ja) | 2009-09-16 |
EP1386923A4 (en) | 2005-08-31 |
US20040132748A1 (en) | 2004-07-08 |
US20070037832A1 (en) | 2007-02-15 |
CA2444130A1 (en) | 2002-10-31 |
KR20040008156A (ko) | 2004-01-28 |
ES2314042T3 (es) | 2009-03-16 |
CA2444130C (en) | 2010-12-21 |
JPWO2002085905A1 (ja) | 2004-08-12 |
DE60228229D1 (de) | 2008-09-25 |
US7157465B2 (en) | 2007-01-02 |
EP1386923A1 (en) | 2004-02-04 |
KR100892614B1 (ko) | 2009-04-09 |
US7521454B2 (en) | 2009-04-21 |
CN1512992A (zh) | 2004-07-14 |
CN1250548C (zh) | 2006-04-12 |
TWI331150B (en) | 2010-10-01 |
EP1386923B1 (en) | 2008-08-13 |
ATE404561T1 (de) | 2008-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002085905A1 (fr) | Nouveaux derives d'adenine | |
JP2004137157A (ja) | 新規アデニン誘導体を有効成分として含有する医薬 | |
JP5997335B2 (ja) | N含有複素環式化合物 | |
ES2549862T3 (es) | Derivados de triazol como inhibidores de quinasa | |
AU2010265932B2 (en) | Heterocyclic compounds and their uses | |
AU2010265974B2 (en) | Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases | |
KR101816942B1 (ko) | 키누레닌 생성 억제 작용을 갖는 함질소 복소환 화합물 | |
KR101563372B1 (ko) | 9-(피라졸-3-일)-9h-푸린-2-아민 및 3-(피라졸-3-일)-3h-이미다조[4,5-b]피리딘-5-아민 유도체 및 암의 치료에서 이의 용도 | |
KR100867484B1 (ko) | 1,3-디히드로이미다졸 축합 고리 화합물 | |
WO2004029054A1 (ja) | 新規アデニン化合物及びその用途 | |
CA2588627A1 (en) | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them | |
WO2009003669A2 (en) | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment | |
CA2806332A1 (en) | Quinoline derivatives and melk inhibitors containing the same | |
KR20110039383A (ko) | cMET 억제제 | |
JP2007510706A (ja) | 痛みを治療するためのバニロイド−1受容体アンタゴニストとしての、置換された含窒素六員アミノ複素環 | |
JP2004515550A (ja) | 治療用化合物 | |
KR20160063026A (ko) | 단백질 키나아제 저해제로 유용한 헤테로아릴아민 유도체 | |
KR20150015501A (ko) | 방향족 복소환 유도체 및 의약 | |
CA3086714A1 (en) | Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitors | |
CN114641474B (zh) | 一类具有免疫调节功能的含n杂环化合物的制备和应用 | |
MX2007007901A (es) | Pirido-(3,2-d)pirimidinas y composiciones farmaceuticas utiles para tratamiento medico. | |
CN115785074B (zh) | Parp7抑制剂及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002583432 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037013459 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2444130 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10474199 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002717152 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028113004 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002717152 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002717152 Country of ref document: EP |